AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Update

AnaptysBio, Inc. (NASDAQ:ANAB) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 6,030,000 shares, a decrease of 8.6% from the January 15th total of 6,600,000 shares. Currently, 23.3% of the company’s shares are short sold. Based on an average daily volume of 662,000 shares, the days-to-cover ratio is currently 9.1 days.

Insider Activity

In other news, Director Ecor1 Capital, Llc acquired 65,184 shares of AnaptysBio stock in a transaction dated Monday, December 30th. The shares were bought at an average cost of $12.92 per share, with a total value of $842,177.28. Following the purchase, the director now owns 7,860,180 shares in the company, valued at $101,553,525.60. This trade represents a 0.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Boxer Capital Management LLC purchased a new stake in shares of AnaptysBio in the fourth quarter valued at about $17,212,000. Northern Trust Corp raised its holdings in shares of AnaptysBio by 10.0% in the fourth quarter. Northern Trust Corp now owns 219,986 shares of the biotechnology company’s stock valued at $2,913,000 after purchasing an additional 20,073 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of AnaptysBio in the fourth quarter valued at about $593,000. Virtus ETF Advisers LLC raised its holdings in shares of AnaptysBio by 24.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 936 shares during the last quarter. Finally, Nebula Research & Development LLC purchased a new stake in shares of AnaptysBio in the fourth quarter valued at about $231,000.

AnaptysBio Trading Up 10.0 %

ANAB opened at $21.22 on Monday. The company’s fifty day moving average price is $15.75 and its two-hundred day moving average price is $25.63. AnaptysBio has a 1-year low of $12.21 and a 1-year high of $41.31. The company has a market cap of $645.72 million and a price-to-earnings ratio of -3.49.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ANAB shares. Truist Financial reduced their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. UBS Group upped their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. HC Wainwright reaffirmed a “neutral” rating and issued a $19.00 price objective on shares of AnaptysBio in a research note on Tuesday, February 4th. Wedbush reissued an “outperform” rating and set a $40.00 target price on shares of AnaptysBio in a research note on Wednesday, February 12th. Finally, Guggenheim cut their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.45.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.